Nova Mentis Life Science Corp. (NMLSF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 31.05 Thousand CAD | -89.53% |
| 2022 | 296.78 Thousand CAD | -66.32% |
| 2021 | 881.15 Thousand CAD | -82.7% |
| 2020 | 5.09 Million CAD | -22.67% |
| 2019 | 6.58 Million CAD | -12.79% |
| 2018 | 7.55 Million CAD | 134.14% |
| 2017 | 3.22 Million CAD | 341.8% |
| 2016 | 729.94 Thousand CAD | 140.51% |
| 2015 | 303.5 Thousand CAD | 10.57% |
| 2014 | 274.49 Thousand CAD | -82.81% |
| 2013 | 1.59 Million CAD | -5.58% |
| 2012 | 1.69 Million CAD | -78.72% |
| 2011 | 7.94 Million CAD | 168.62% |
| 2010 | 2.95 Million CAD | -29.42% |
| 2009 | 4.19 Million CAD | 118.75% |
| 2008 | 1.91 Million CAD | 18.68% |
| 2007 | 1.61 Million CAD | 136.48% |
| 2006 | 682.95 Thousand CAD | 323.29% |
| 2005 | 161.34 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 40.09 Thousand CAD | 29.1% |
| 2024 Q2 | 26.34 Thousand CAD | -34.29% |
| 2023 FY | 31.05 Thousand CAD | -89.53% |
| 2023 Q3 | 53.88 Thousand CAD | -12.35% |
| 2023 Q1 | 229.26 Thousand CAD | -22.75% |
| 2023 Q4 | 31.05 Thousand CAD | -42.36% |
| 2023 Q2 | 61.47 Thousand CAD | -73.19% |
| 2022 Q3 | 1.15 Million CAD | -14.96% |
| 2022 FY | 296.78 Thousand CAD | -66.32% |
| 2022 Q1 | 1.83 Million CAD | 108.21% |
| 2022 Q2 | 1.36 Million CAD | -25.68% |
| 2022 Q4 | 296.78 Thousand CAD | -74.4% |
| 2021 Q1 | 4.36 Million CAD | -14.29% |
| 2021 Q2 | 3.98 Million CAD | -8.64% |
| 2021 Q3 | 3.38 Million CAD | -15.02% |
| 2021 Q4 | 881.15 Thousand CAD | -73.99% |
| 2021 FY | 881.15 Thousand CAD | -82.7% |
| 2020 Q1 | 6.34 Million CAD | -3.61% |
| 2020 Q4 | 5.09 Million CAD | -29.04% |
| 2020 FY | 5.09 Million CAD | -22.67% |
| 2020 Q3 | 7.17 Million CAD | -2.87% |
| 2020 Q2 | 7.38 Million CAD | 16.39% |
| 2019 Q3 | 6.84 Million CAD | -1.86% |
| 2019 Q4 | 6.58 Million CAD | -3.78% |
| 2019 FY | 6.58 Million CAD | -12.79% |
| 2019 Q1 | 7.27 Million CAD | -3.66% |
| 2019 Q2 | 6.97 Million CAD | -4.13% |
| 2018 Q4 | 7.55 Million CAD | -1.68% |
| 2018 Q3 | 7.67 Million CAD | 1.82% |
| 2018 Q2 | 7.54 Million CAD | -1.87% |
| 2018 Q1 | 7.68 Million CAD | 138.35% |
| 2018 FY | 7.55 Million CAD | 134.14% |
| 2017 Q1 | 1 Million CAD | 37.03% |
| 2017 Q4 | 3.22 Million CAD | 298.97% |
| 2017 Q3 | 808.31 Thousand CAD | -18.37% |
| 2017 FY | 3.22 Million CAD | 341.8% |
| 2017 Q2 | 990.23 Thousand CAD | -1.0% |
| 2016 Q2 | 194.69 Thousand CAD | -16.84% |
| 2016 FY | 729.94 Thousand CAD | 140.51% |
| 2016 Q3 | 117.78 Thousand CAD | -39.5% |
| 2016 Q1 | 234.13 Thousand CAD | -22.86% |
| 2016 Q4 | 729.94 Thousand CAD | 519.72% |
| 2015 Q1 | 161.64 Thousand CAD | -41.11% |
| 2015 Q4 | 303.5 Thousand CAD | 100.52% |
| 2015 Q3 | 151.36 Thousand CAD | 181.86% |
| 2015 Q2 | 53.7 Thousand CAD | -66.78% |
| 2015 FY | 303.5 Thousand CAD | 10.57% |
| 2014 Q3 | 1.88 Million CAD | 10.22% |
| 2014 Q1 | 1.7 Million CAD | 6.99% |
| 2014 FY | 274.49 Thousand CAD | -82.81% |
| 2014 Q4 | 274.49 Thousand CAD | -85.46% |
| 2014 Q2 | 1.71 Million CAD | 0.26% |
| 2013 Q1 | 1.67 Million CAD | -1.09% |
| 2013 Q2 | 1.64 Million CAD | -1.56% |
| 2013 Q3 | 1.69 Million CAD | 3.15% |
| 2013 FY | 1.59 Million CAD | -5.58% |
| 2013 Q4 | 1.59 Million CAD | -6.0% |
| 2012 Q4 | 1.69 Million CAD | -77.89% |
| 2012 Q2 | 7.66 Million CAD | -1.11% |
| 2012 Q1 | 7.74 Million CAD | -2.52% |
| 2012 FY | 1.69 Million CAD | -78.72% |
| 2012 Q3 | 7.64 Million CAD | -0.18% |
| 2011 FY | 7.94 Million CAD | 168.62% |
| 2011 Q4 | 7.94 Million CAD | -17.62% |
| 2011 Q3 | 9.65 Million CAD | 188.19% |
| 2011 Q2 | 3.34 Million CAD | -5.5% |
| 2011 Q1 | 3.54 Million CAD | 19.74% |
| 2010 Q4 | 2.95 Million CAD | -13.07% |
| 2010 Q1 | 3.58 Million CAD | -14.48% |
| 2010 Q2 | 3.5 Million CAD | -2.15% |
| 2010 Q3 | 3.4 Million CAD | -2.96% |
| 2010 FY | 2.95 Million CAD | -29.42% |
| 2009 FY | 4.19 Million CAD | 118.75% |
| 2009 Q4 | 4.19 Million CAD | 5.98% |
| 2009 Q3 | 3.95 Million CAD | 42.34% |
| 2009 Q2 | 2.77 Million CAD | 9.21% |
| 2009 Q1 | 2.54 Million CAD | 32.78% |
| 2008 Q2 | 1.98 Million CAD | 27.15% |
| 2008 FY | 1.91 Million CAD | 18.68% |
| 2008 Q1 | 1.56 Million CAD | -3.37% |
| 2008 Q3 | 2.13 Million CAD | 7.53% |
| 2008 Q4 | 1.91 Million CAD | -10.18% |
| 2007 FY | 1.61 Million CAD | 136.48% |
| 2007 Q3 | 1.67 Million CAD | -5.79% |
| 2007 Q4 | 1.61 Million CAD | -3.63% |
| 2007 Q2 | 1.77 Million CAD | 8.68% |
| 2007 Q1 | 1.63 Million CAD | 139.65% |
| 2006 Q3 | 769.84 Thousand CAD | 428.13% |
| 2006 Q4 | 682.95 Thousand CAD | -11.29% |
| 2006 FY | 682.95 Thousand CAD | 323.29% |
| 2006 Q2 | 145.76 Thousand CAD | 0.0% |
| 2005 FY | 161.34 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.92% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 99.57% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.971% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.706% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.976% |
| Mesoblast Limited | 667.9 Million USD | 99.995% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | 57.08% |
| Genus plc | 1.02 Billion USD | 99.997% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 97.713% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 93.776% |
| Marizyme, Inc. | 22.01 Million USD | 99.859% |
| ContraFect Corporation | 20.67 Million USD | 99.85% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 95.046% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 92.044% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 91.873% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 97.831% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 99.251% |
| MultiCell Technologies, Inc. | 126.22 USD | -24507.035% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 96.695% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.976% |
| EV Biologics, Inc. | 431.71 Thousand USD | 92.806% |
| Q BioMed Inc. | 3.51 Million USD | 99.117% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.912% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 95.97% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 88.113% |
| Biomind Labs Inc. | 73.81 Thousand USD | 57.925% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 99.993% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.897% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.74% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 99.063% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 98.869% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 98.414% |
| IMV Inc. | 31.33 Million USD | 99.901% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 95.482% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 98.807% |
| GB Sciences, Inc. | 103.44 Thousand USD | 69.974% |
| Alpha Cognition Inc. | 2.45 Million USD | 98.733% |
| HST Global, Inc. | 1526.00 USD | -1935.321% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Halberd Corporation | 10.13 Thousand USD | -206.574% |
| Enzolytics Inc. | 361.7 Million USD | 99.991% |
| Resverlogix Corp. | 8.11 Million USD | 99.617% |
| Affymax, Inc. | 7.44 Million USD | 99.583% |
| SYBLEU INC | 330.46 Thousand USD | 90.602% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 98.346% |
| argenx SE | 4.54 Billion USD | 99.999% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.889% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.935% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -36.337% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 99.653% |
| AVAX Technologies, Inc. | 7.37 Million USD | 99.579% |
| Zenith Capital Corp. | 7410.00 USD | -319.15% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.999% |
| Ember Therapeutics, Inc. | 184.00 USD | -16779.891% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 90.349% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 88.117% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.993% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 97.856% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | 98.973% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.941% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 96.653% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.787% |
| ONE Bio Corp. | 70.08 Million USD | 99.956% |
| Reve Technologies, Inc. | 57.09 Thousand USD | 45.6% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -1244.545% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 96.856% |
| Agentix Corp. | 261.39 Thousand USD | 88.118% |
| LadRx Corporation | 2.3 Million USD | 98.654% |
| Cell Source, Inc. | 195.17 Thousand USD | 84.086% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 93.537% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 91.217% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 91.217% |
| NovAccess Global Inc. | 62.24 Thousand USD | 50.104% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 95.144% |
| Itoco Inc. | 1.4 Million USD | 97.782% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 67.531% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 70.699% |
| Kadimastem Ltd | 2.3 Million USD | 98.652% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | 59.322% |
| CytoDyn Inc. | 11.13 Million USD | 99.721% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 78.276% |
| Mobile Lads Corp. | 52.00 USD | -59628.846% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -73.708% |
| Qrons Inc. | 420.00 USD | -7295.0% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 91.943% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 94.375% |
| Rebus Holdings, Inc. | 5000.00 USD | -521.18% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 92.414% |
| International Stem Cell Corporation | 5.39 Million USD | 99.424% |
| Bioxytran, Inc. | 137.63 Thousand USD | 77.434% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.793% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.813% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 60.685% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 96.408% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 99.587% |
| Neutra Corp. | 2851.00 USD | -989.407% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.904% |
| PureTech Health plc | 693.97 Million USD | 99.996% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 99.615% |
| IXICO plc | 15.84 Million USD | 99.804% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 99.625% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.97% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.991% |